ะะฐะป ะ ะฐั ัะป ะัะผะฐั
ะ ัะตะฑะต
๐๐๐ฒ ๐๐ฏ๐๐ซ๐ฒ๐จ๐ง๐;
๐๐๐ซ๐ฆ ๐ฐ๐๐ฅ๐๐จ๐ฆ๐ ๐ญ๐จ ๐ฆ๐ฒ ๐ฉ๐ซ๐จ๐๐ข๐ฅ๐, Working as "๐๐ฌ๐ฌ๐ข๐ฌ๐ญ๐๐ง๐ญ ๐๐ซ๐จ๐๐๐ฌ๐ฌ๐จ๐ซ", ๐๐๐ฉ๐๐ซ๐ญ๐ฆ๐๐ง๐ญ ๐จ๐ ๐๐ก๐๐ซ๐ฆ๐๐๐ฒ, ๐๐๐ ๐๐ง๐ง๐๐ญ๐ก ๐๐ง๐ข๐ฏ๐๐ซ๐ฌ๐ข๐ญ๐ฒ, ๐๐ก๐๐ค๐ฌ๐ฎ, ๐๐๐ข๐ฉ๐ฎ๐ซ, ๐๐๐ฃ๐๐ฌ๐ญ๐ก๐๐ง, ๐๐ง๐๐ข๐. I had completed my ๐๐๐๐ก๐๐ฅ๐จ๐ซ ๐จ๐ ๐๐ก๐๐ซ๐ฆ๐๐๐ฒ (๐. ๐๐ก๐๐ซ๐ฆ) ๐๐ซ๐จ๐ฆ ๐๐ง๐ฏ๐๐ซ๐ญ๐ข๐ฌ ๐๐ง๐ข๐ฏ๐๐ซ๐ฌ๐ข๐ญ๐ฒ, ๐๐๐ซ๐๐ข๐ฅ๐ฅ๐ฒ, ๐๐. ๐๐ง๐๐ข๐. and ๐. ๐๐ก๐๐ซ๐ฆ (๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐ฌ) ๐๐ซ๐จ๐ฆ ๐๐ข๐ฆ๐ฌ ๐๐ง๐ฌ๐ญ๐ข๐ญ๐ฎ๐ญ๐ ๐จ๐ ๐๐ก๐๐ซ๐ฆ๐๐๐ฒ, ๐๐ข๐ฆ๐ฌ ๐๐ง๐ข๐ฏ๐๐ซ๐ฌ๐ข๐ญ๐ฒ ๐๐๐ฃ๐๐ฌ๐ญ๐ก๐๐ง, ๐๐๐ข๐ฉ๐ฎ๐ซ ๐๐๐๐๐๐, ๐๐ง๐๐ข๐.
๐๐ฉ๐๐๐ข๐๐ฅ๐ข๐ณ๐๐ญ๐ข๐จ๐ง: "Pharmaceutics".
As a Master's, I had gain lots of knowledge about academics and learning of skills for my profession to increasing my skills. Currently, continues working on review articles, research papers and books writing work etc..
โฆฟ I had published ๐๐ ๐๐๐ฏ๐ข๐๐ฐ ๐๐ซ๐ญ๐ข๐๐ฅ๐๐ฌ (Elsevier*/Bentham/Scopus/PubMed) and ๐๐ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐ซ๐ญ๐ข๐๐ฅ๐๐ฌ with my acquired knowledge.
โฆฟ I had published and Granted ๐๐ ๐๐ง๐๐ข๐๐ง ๐๐๐ฌ๐ข๐ ๐ง ๐๐๐ซ๐ญ๐ข๐๐ข๐๐๐ญ๐, ๐๐ ๐๐ง๐ญ๐๐ซ๐ง๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ Design Patent and ๐ ๐๐ญ๐ข๐ฅ๐ข๐ญ๐ฒ ๐๐ฎ๐๐ฅ๐ข๐๐๐ญ๐ข๐จ๐ง under IPR.
โฆฟ I had attended ๐๐ ๐๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐จ๐ง๐๐๐ซ๐๐ง๐๐, ๐๐ ๐จ๐ซ๐๐ฅ ๐-๐ฉ๐จ๐ฌ๐ญ๐๐ซ ๐ฉ๐ซ๐๐ฌ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง and ๐๐ ๐๐๐ฌ๐ญ๐ซ๐๐๐ญ ๐ฌ๐ฎ๐๐ฆ๐ข๐ญ๐ญ๐๐ in conference.
โฆฟ I had participated in ๐๐ ๐๐ง๐ญ๐๐ซ๐ง๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐จ๐ง๐๐๐ซ๐๐ง๐๐๐ฌ, ๐๐ ๐๐๐ฌ๐ญ๐ซ๐๐๐ญ ๐ฌ๐ฎ๐๐ฆ๐ข๐ญ๐ญ๐๐ and ๐๐ ๐๐ซ๐๐ฅ ๐ฉ๐๐ฉ๐๐ซ ๐ฉ๐ซ๐๐ฌ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง conducted by Eudoxia Research University, New Castle, USA.
โฆฟ I had attended and participated in ๐๐ ๐ ๐๐ ๐๐ญ I๐ง๐ญ๐๐ซ๐ง๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐ฅ๐๐ฏ๐๐ฅ.
โฆฟ I had attended ๐๐ ๐๐ง๐ญ๐๐ซ๐ง๐๐ญ๐ข๐จ๐ง๐๐ฅ/๐๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐จ๐ซ๐ค๐ฌ๐ก๐จ๐ฉ and ๐๐ง๐ญ๐๐ซ๐ง๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ฒ๐ฆ๐ฉ๐จ๐ฌ๐ข๐ฎ๐ฆ ๐๐ as my achievement.
โฆฟ I had recently published ๐๐ ๐๐ฒ๐ ๐ ๐๐ผ๐ผ๐ธ๐ at D. Pharm, B. Pharm and M. Pharm level students [KDP, JEC Publishers and Pritam Publications]
โฆฟ I had recently published 01 ๐๐ฒ๐ ๐ ๐๐ผ๐ผ๐ธ๐ [๐๐จ๐ฅ๐๐๐ฎ๐ฅ๐๐ซ ๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐ฌ] at M. Pharm level students with ๐๐ ๐๐ฎ๐๐ฅ๐ข๐๐๐ญ๐ข๐จ๐ง๐ฌ.
โฆฟ ๐ฅ๐ฒ๐๐ฒ๐ฎ๐ฟ๐ฐ๐ต๐๐ฎ๐๐ฒ ๐ฆ๐๐ฎ๐๐: I got ๐,๐๐๐+ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐ง๐ญ๐๐ซ๐๐ฌ๐ญ ๐๐๐จ๐ซ๐๐ฌ, ๐๐๐,๐๐๐+ ๐ซ๐๐๐๐ฌ, ๐๐๐ ๐๐ข๐ญ๐๐ญ๐ข๐จ๐ง๐ฌ (๐ก-๐ข๐ง๐๐๐ฑ ๐) ๐๐ง๐ ๐๐๐+ ๐ซ๐๐๐จ๐ฆ๐ฆ๐๐ง๐๐๐ญ๐ข๐จ๐ง๐ฌ ๐จ๐ง ๐ฆ๐ฒ ๐๐๐ฌ๐๐๐ซ๐๐ก๐๐๐ญ๐ ๐ฉ๐ซ๐จ๐๐ข๐ฅ๐.
โฆฟ ๐๐ผ๐ผ๐ด๐น๐ฒ ๐ฆ๐ฐ๐ต๐ผ๐น๐ฎ๐ฟ ๐ฆ๐๐ฎ๐๐: I had contributed with ๐๐๐ ๐๐ข๐ญ๐๐ญ๐ข๐จ๐ง, ๐ก-๐ข๐ง๐๐๐ฑ ๐ ๐๐ง๐ 4 ๐ข๐๐-๐ข๐ง๐๐๐ฑ on it.
โฆฟ I'm ๐ซ๐๐ฏ๐ข๐๐ฐ๐๐ซ ๐๐จ๐๐ซ๐ ๐ฆ๐๐ฆ๐๐๐ซ ๐จ๐ ๐ฆ๐จ๐ซ๐ ๐ญ๐ก๐๐ง 25 Google scholar and NLM based journals, and ๐๐ ๐๐๐ ๐จ๐ ๐๐๐ข๐๐ง๐๐ ๐๐จ๐ฎ๐ซ๐ง๐๐ฅ.
โฆฟ Providing Turnitin plag. report quickly for the Review, Research, Thesis and other related documents checking.
ะะฑะปะฐััะธ ะฝะฐััะฝัั ะธะฝัะตัะตัะพะฒ
ะะฑัะฐะทะพะฒะฐะฝะธะต
ะขะพะฟ-100
ะััะฝะฐะปั
|
1
2
3
4
5
|
|
|
Journal of Drug Delivery and Therapeutics
5 ะฟัะฑะปะธะบะฐัะธะน, 13.89%
|
|
|
Drug Delivery Letters
2 ะฟัะฑะปะธะบะฐัะธะธ, 5.56%
|
|
|
Nanoscience and Nanotechnology - Asia
2 ะฟัะฑะปะธะบะฐัะธะธ, 5.56%
|
|
|
Current Nanomedicine
2 ะฟัะฑะปะธะบะฐัะธะธ, 5.56%
|
|
|
Advances in Research
2 ะฟัะฑะปะธะบะฐัะธะธ, 5.56%
|
|
|
Recent Advances in Drug Delivery and Formulation
2 ะฟัะฑะปะธะบะฐัะธะธ, 5.56%
|
|
|
Journal of Pharmacognosy and Phytochemistry
2 ะฟัะฑะปะธะบะฐัะธะธ, 5.56%
|
|
|
iScience
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Journal of Microencapsulation
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Pharmaceutical Nanotechnology
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Current Rheumatology Reviews
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Journal of Drug Delivery Science and Technology
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Current Aging Science
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Journal of Pharmaceutical Research International
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
International Journal of Pharmaceutical Investigation
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Journal of Advances in Medicine and Medical Research
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Asian Journal of Research in Computer Science
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
International Research Journal of Modernization in Engineering Technology and Science
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
International Journal of Pharmaceutical Sciences and Medicine
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
International Journal of Computing and Artificial Intelligence
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
1
2
3
4
5
|
ะฆะธัะธััััะธะต ะถััะฝะฐะปั
ะฆะธัะธััะตะผัะต ะถััะฝะฐะปั
ะะทะดะฐัะตะปะธ
|
2
4
6
8
10
12
|
|
|
Bentham Science Publishers Ltd.
11 ะฟัะฑะปะธะบะฐัะธะน, 30.56%
|
|
|
Sciencedomain International
5 ะฟัะฑะปะธะบะฐัะธะน, 13.89%
|
|
|
Society of Pharmaceutical Tecnocrats
5 ะฟัะฑะปะธะบะฐัะธะน, 13.89%
|
|
|
Elsevier
2 ะฟัะฑะปะธะบะฐัะธะธ, 5.56%
|
|
|
AkiNik Publications
2 ะฟัะฑะปะธะบะฐัะธะธ, 5.56%
|
|
|
Taylor & Francis
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
MANUSCRIPT TECHNOMEDIA LLP
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Comprehensive Publications
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
Zain Publications
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
International Research Journal of Modernization in Engineering Technology and Science
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
2
4
6
8
10
12
|
ะัะณะฐะฝะธะทะฐัะธะธ ะธะท ะฟัะฑะปะธะบะฐัะธะน
|
5
10
15
20
25
|
|
|
ะัะณะฐะฝะธะทะฐัะธั ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ
|
ะัะณะฐะฝะธะทะฐัะธั ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ, 22, 61.11%
ะัะณะฐะฝะธะทะฐัะธั ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ
22 ะฟัะฑะปะธะบะฐัะธะธ, 61.11%
|
|
ะฃะฝะธะฒะตััะธัะตัะฐ ะงะธัะบะฐัะฐ
7 ะฟัะฑะปะธะบะฐัะธะน, 19.44%
|
|
|
ะฃะฝะธะฒะตััะธัะตั ะ ะฐะดะถะฐััะฐะฝะฐ
4 ะฟัะฑะปะธะบะฐัะธะธ, 11.11%
|
|
|
ะฃะฝะธะฒะตััะธัะตั ะะะะก
4 ะฟัะฑะปะธะบะฐัะธะธ, 11.11%
|
|
|
ะะตะฝะดะถะฐะฑัะบะธะน ัะตั
ะฝะธัะตัะบะธะน ัะฝะธะฒะตััะธัะตั ะ. ะ. ะัะดะถัะฐะปะฐ
3 ะฟัะฑะปะธะบะฐัะธะธ, 8.33%
|
|
|
ะะถะฐะผะธั ะฅะฐะผะดะฐัะด
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
JSS ะะบะฐะดะตะผะธั ะฒัััะตะณะพ ะพะฑัะฐะทะพะฒะฐะฝะธั ะธ ะธััะปะตะดะพะฒะฐะฝะธะน
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
ะฃะฝะธะฒะตััะธัะตั ะะฐั
ะฐัะธัะธ ะะฐัะบะฐะฝะดะตัะฒะฐัะฐ, ะัะปะปะฐะฝะฐ
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
ะะฐััะฐัััะตััะบะฐั ะฑะพะปัะฝะธัะฐ ะพะฑัะตะณะพ ะฟัะพัะธะปั
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
ะะตะดะธัะธะฝัะบะฐั ัะบะพะปะฐ ะธะผะตะฝะธ ะงะฐะฝะฐ ะฟัะธ ะะฐััะฐัััะตััะบะพะผ ัะฝะธะฒะตััะธัะตัะต
1 ะฟัะฑะปะธะบะฐัะธั, 2.78%
|
|
|
5
10
15
20
25
|
ะกััะฐะฝั ะธะท ะฟัะฑะปะธะบะฐัะธะน
|
5
10
15
20
25
30
|
|
|
ะกััะฐะฝะฐ ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ
|
ะกััะฐะฝะฐ ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ, 28, 77.78%
ะกััะฐะฝะฐ ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ
28 ะฟัะฑะปะธะบะฐัะธะน, 77.78%
|
|
ะะฝะดะธั
|
ะะฝะดะธั, 13, 36.11%
ะะฝะดะธั
13 ะฟัะฑะปะธะบะฐัะธะน, 36.11%
|
|
ะกะจะ
|
ะกะจะ, 5, 13.89%
ะกะจะ
5 ะฟัะฑะปะธะบะฐัะธะน, 13.89%
|
|
5
10
15
20
25
30
|
ะฆะธัะธััััะธะต ะพัะณะฐะฝะธะทะฐัะธะธ
ะฆะธัะธััััะธะต ัััะฐะฝั
|
5
10
15
20
25
30
35
|
|
|
ะกััะฐะฝะฐ ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ
|
ะกััะฐะฝะฐ ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ, 35, 36.46%
ะกััะฐะฝะฐ ะฝะต ะพะฟัะตะดะตะปะตะฝะฐ
35 ัะธัะธัะพะฒะฐะฝะธะน, 36.46%
|
|
ะะฝะดะธั
|
ะะฝะดะธั, 23, 23.96%
ะะฝะดะธั
23 ัะธัะธัะพะฒะฐะฝะธั, 23.96%
|
|
ะะธัะฐะน
|
ะะธัะฐะน, 6, 6.25%
ะะธัะฐะน
6 ัะธัะธัะพะฒะฐะฝะธะน, 6.25%
|
|
ะัะฐะปะธั
|
ะัะฐะปะธั, 5, 5.21%
ะัะฐะปะธั
5 ัะธัะธัะพะฒะฐะฝะธะน, 5.21%
|
|
ะกะจะ
|
ะกะจะ, 4, 4.17%
ะกะจะ
4 ัะธัะธัะพะฒะฐะฝะธั, 4.17%
|
|
ะขะฐะธะปะฐะฝะด
|
ะขะฐะธะปะฐะฝะด, 4, 4.17%
ะขะฐะธะปะฐะฝะด
4 ัะธัะธัะพะฒะฐะฝะธั, 4.17%
|
|
ะะฐะปะฐะนะทะธั
|
ะะฐะปะฐะนะทะธั, 3, 3.13%
ะะฐะปะฐะนะทะธั
3 ัะธัะธัะพะฒะฐะฝะธั, 3.13%
|
|
ะะฐะบะธััะฐะฝ
|
ะะฐะบะธััะฐะฝ, 3, 3.13%
ะะฐะบะธััะฐะฝ
3 ัะธัะธัะพะฒะฐะฝะธั, 3.13%
|
|
ะขัััะธั
|
ะขัััะธั, 3, 3.13%
ะขัััะธั
3 ัะธัะธัะพะฒะฐะฝะธั, 3.13%
|
|
ะะณะธะฟะตั
|
ะะณะธะฟะตั, 2, 2.08%
ะะณะธะฟะตั
2 ัะธัะธัะพะฒะฐะฝะธั, 2.08%
|
|
ะัะฐะฝ
|
ะัะฐะฝ, 2, 2.08%
ะัะฐะฝ
2 ัะธัะธัะพะฒะฐะฝะธั, 2.08%
|
|
ะกะฐัะดะพะฒัะบะฐั ะัะฐะฒะธั
|
ะกะฐัะดะพะฒัะบะฐั ะัะฐะฒะธั, 2, 2.08%
ะกะฐัะดะพะฒัะบะฐั ะัะฐะฒะธั
2 ัะธัะธัะพะฒะฐะฝะธั, 2.08%
|
|
ะะฒัััะฐะปะธั
|
ะะฒัััะฐะปะธั, 1, 1.04%
ะะฒัััะฐะปะธั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะะฐะฝะฐ
|
ะะฐะฝะฐ, 1, 1.04%
ะะฐะฝะฐ
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะะพะฝะบะพะฝะณ (ะกะะ )
|
ะะพะฝะบะพะฝะณ (ะกะะ ), 1, 1.04%
ะะพะฝะบะพะฝะณ (ะกะะ )
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะะฝะดะพะฝะตะทะธั
|
ะะฝะดะพะฝะตะทะธั, 1, 1.04%
ะะฝะดะพะฝะตะทะธั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะัะฐะบ
|
ะัะฐะบ, 1, 1.04%
ะัะฐะบ
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะัะปะฐะฝะดะธั
|
ะัะปะฐะฝะดะธั, 1, 1.04%
ะัะปะฐะฝะดะธั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะัะฟะฐะฝะธั
|
ะัะฟะฐะฝะธั, 1, 1.04%
ะัะฟะฐะฝะธั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะะพะปัะผะฑะธั
|
ะะพะปัะผะฑะธั, 1, 1.04%
ะะพะปัะผะฑะธั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะะพะฒะฐั ะะตะปะฐะฝะดะธั
|
ะะพะฒะฐั ะะตะปะฐะฝะดะธั, 1, 1.04%
ะะพะฒะฐั ะะตะปะฐะฝะดะธั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะะะญ
|
ะะะญ, 1, 1.04%
ะะะญ
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะะพะปััะฐ
|
ะะพะปััะฐ, 1, 1.04%
ะะพะปััะฐ
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะ ะตัะฟัะฑะปะธะบะฐ ะะพัะตั
|
ะ ะตัะฟัะฑะปะธะบะฐ ะะพัะตั, 1, 1.04%
ะ ะตัะฟัะฑะปะธะบะฐ ะะพัะตั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะ ัะผัะฝะธั
|
ะ ัะผัะฝะธั, 1, 1.04%
ะ ัะผัะฝะธั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะฃะทะฑะตะบะธััะฐะฝ
|
ะฃะทะฑะตะบะธััะฐะฝ, 1, 1.04%
ะฃะทะฑะตะบะธััะฐะฝ
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะญัะธะพะฟะธั
|
ะญัะธะพะฟะธั, 1, 1.04%
ะญัะธะพะฟะธั
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
ะฎะะ
|
ะฎะะ , 1, 1.04%
ะฎะะ
1 ัะธัะธัะพะฒะฐะฝะธะต, 1.04%
|
|
5
10
15
20
25
30
35
|
- ะั ะฝะต ััะธััะฒะฐะตะผ ะฟัะฑะปะธะบะฐัะธะธ, ั ะบะพัะพััั ะฝะตั DOI.
- ะกัะฐัะธััะธะบะฐ ะฟะตัะตััะธััะฒะฐะตััั ัะฐะท ะฒ ัััะบะธ.